Sumeyye AYDOGAN TURKOGLU, Gizem DAYİ, Feray KOCKAR

Upregulation of PSMD4 gene by hypoxia in prostate cancer cells

Ubiquitin-proteasome pathways have a crucial role in tumor progression. PSMD4 (Rpn10, 26S proteasome non-ATPase subunit 4), which is a subunit of the regulatory particle, is a major ubiquitin (Ub) receptor of 26S proteasome. PSMD4 overexpression has been observed in colon carcinoma, hepatocellular carcinoma, and breast cancer. In this work, we elucidated the effect of hypoxia on PSMD4 gene expression in prostate cancer cells (PC3). Chemically mimicked hypoxia drastically upregulated PSMD4 gene expression at both mRNA and protein levels. Transient transfection experiments indicated that all promoter fragments were active in PC3 cells. Hypoxia increased transcriptional activity of all PSMD4 promoter constructs. EMSA analysis shows that HIF-1a transcription factor binds to the hypoxia response element (HRE) present within the -98/+52 region of PSMD4 promoter. We also used human umbilical vein endothelial cell (HUVEC) as a different cell model, in which increased PSMD4 expression was seen only at 24 h. The increased expression of the PSMD4 level in the PC3 cell line was not parallel to the expression in hypoxic HUVEC.

Keywords:

PSMD4, hypoxia transcriptional regulation, prostate cancer, endothelial cells,

PDF

___

Aydemir AT, 2018, GENE, V659, P1, DOI 10.1016/j.gene.2018.03.009
Benaroudj N, 2003, MOL CELL, V11, P69, DOI 10.1016/S1097-2765(02)00775-X
Cai MJ, 2019, GENE, V702, P66, DOI 10.1016/j.gene.2019.03.063
Chen YJ, 2016, CANCER LETT, V379, P245, DOI 10.1016/j.canlet.2015.06.023
Cheng Ya-Min, 2018, Oncotarget, V9, P26342, DOI 10.18632/oncotarget.25254
Collins GA, 2017, CELL, V169, P792, DOI 10.1016/j.cell.2017.04.023
Deep Gagan, 2015, Critical Reviews in Oncogenesis, V20, P419, DOI 10.1615/CritRevOncog.v20.i5-6.130
Fejzo MS, 2017, GENE CHROMOSOME CANC, V56, P589, DOI 10.1002/gcc.22459
Godek J, 2011, EXP MOL PATHOL, V90, P244, DOI 10.1016/j.yexmp.2011.01.002
Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704
Koyasu S, 2018, CANCER SCI, V109, P560, DOI 10.1111/cas.13483
Lee JE, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39843-6
Liang YM, 2017, BIOCHEM BIOPH RES CO, V490, P567, DOI 10.1016/j.bbrc.2017.06.079
Lin PL, 2016, FREE RADICAL BIO MED, V95, P121, DOI 10.1016/j.freeradbiomed.2016.03.014
Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
Marignol L, 2005, CANCER BIOL THER, V4, P359
Nelson JE, 2000, J LAB CLIN MED, V135, P324, DOI 10.1067/mlc.2000.105615
Patel A, 2016, BIOTECHNOL ADV, V34, P803, DOI 10.1016/j.biotechadv.2016.04.005
Shen M, 2013, EXPERT OPIN THER TAR, V17, P1091, DOI 10.1517/14728222.2013.815728
Tian C, 2019, IEEE SYMP COMP COMMU, P100
Tokay E, 2016, MOL CELL BIOCHEM, V423, P75, DOI 10.1007/s11010-016-2826-7
Torii S, 2009, J BIOCHEM, V146, P839, DOI 10.1093/jb/mvp129
Turkoglu SA, 2015, FEBS J, V282, P82 .
Turkoglu SA, 2019, ARCH BIOL SCI, V71, P393, DOI 10.2298/ABS181008020A
Turkoglu Sumeyye Aydogan, 2018, HACETTEPE JOURNAL OF BIOLOGY AND CHEMISTRY, V46, P329, DOI 10.15671/HJBC.2018.241
Turkoglu SA, 2016, GENE, V575, P48, DOI 10.1016/j.gene.2015.08.035
WANG GL, 1993, J BIOL CHEM, V268, P21513
WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510
Weidemann A, 2008, CELL DEATH DIFFER, V15, P621, DOI 10.1038/cdd.2008.12
Wu JB, 2015, MOL MED REP, V11, P2677, DOI 10.3892/mmr.2014.3093
Yuan Y, 2003, J BIOL CHEM, V278, P15911, DOI 10.1074/jbc.M300463200
Zhong H, 1999, CANCER RES, V59, P5830 .